Journal Information
Vol. 18. Issue 10.
Pages 626-628 (December 2022)
Download PDF
More article options
Vol. 18. Issue 10.
Pages 626-628 (December 2022)
Letter to the Editor
Full text access
Long COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome: Similarities and differences of two peas in a pod
COVID-19 persistente y encefalomielitis miálgica/síndrome de fatiga crónica: similitudes y diferencias
Rami Qanneta
Internal Medicine, Hospital Sociosanitari Francolí, Tarragona, Spain
This item has received
Article information
Full Text
Download PDF
Full Text
Dear Editor,

Coronavirus disease 2019 (COVID-19) is a highly contagious respiratory disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Prolonged recovery of COVID-19 symptoms, so-called Long COVID-19, has been described even in patients who have mild symptoms and did not required hospitalisation. Various studies showed that at least one out of ten COVID-19 symptomatic patients develop Long COVID-19.1

Although there is an absence of a evidence-based clinical practice guidelines neither a clear aetiopatogenesis, a clinical case definition of post-COVID-19 condition was proposed across the International Severe Respiratory and Emerging Infection Consortium (ISARIC) and the World Health Organization (WHO). Long COVID-19 occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis.2

Patients may present with a multifaced and marked variability of non-specific symptoms that might be fluctuate or relapse over time. Common symptoms include fatigue, pain, dispnoea, sleep disturbances, physical sequelae, psychological distress, and cognitive impairment but also others which generaly have an impact on quality of life. Symptoms may be persist from the initial illness or new onset, following initial recovery from an acute COVID-19 epsiode.2 These clinical manifestations can lead to symptoms commonly presented in patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

ME/CFS is a long-term complicated, heterogeneous, multisystemic and disabling disorder, that was first proposed in 1988 by Holmes et al. to redefine the chronic mononucleosis syndrome as a post-viral fatigue syndrome (PVFS). It is diagnosed according to the 1994 Fukuda criteria, the Canadian consensus document published in 2003 or, more recently, the international consensus criteria of 2011; that offers a review on its physiopathology, symptoms and treatment.3

It is characterised by prolonged generalised and abnormal fatigue after exercise and non-remitting significantly with rest, recurrent headache and problems of concentration and memory, which are of recent appearance and that have lasted for at least 6 months. It is accompanied by such other symptoms as tender lymph nodes, musculoskeletal pain, sleep disruption and psychiatric problems.4

Although the cause is unclear, research into the aetiopatogenesis is ongoing. Female sex, type A personality, and family aggregation are established as a predisposing factors. Infectious agents (human herpesvirus family), toxicity exposure, and psychological and social experience are associated as a precipitating and trigger factors. Other conditions such as advanced age, delay in diagnosis, severe initial involvement, comorbidity, and adaptive disorder are those that maintain the illness once it has become established. Accumulating data indicates a relationship between redox imbalance, mitochondrial dysfunction and oxidative stress pathways in patients with ME/CFS. These abnormalities were also found in patients with Long COVID-19 and suggests that the two disorders may share common pathophysiological features.

However, any potential relationship between ME/CFS and Long COVID-19 is complicated, due to the great heterogeneity of both in its clinical expression and the lack of sensitive screening and standardised instruments to order its different symptoms or agreement regarding the diagnostic criteria. Based on the hypothesis that post-COVID-19 patients can develop a PVFS that is very strikingly similar to ME/CFS, we suggest subagrouping patients with Long COVID-19 into two clinical clustering phenotypes (Table 1).

Table 1.

similarities and differences between Long COVID-19 and ME/CFS.

Pathological entities  ME/CFS  Long COVID-19
Prevalence  0.5–2.5% of general population  10–12.2% of COVID-19 patients after acute episode79% were hospitalised during acute episode (inpatient)
Gender F/M  4:1  1:1Male gender is slightly prevalent (56%)
Age  Bimodal incidence15–20 years33–45 years  40–55 yearsMean age 54.4 years
Aetiology related to infectious agents  HHV (Human Herpesvirus family)SARS-CoV-1MERS-CoV  SARS-CoV-2
Patogenesis  Redox imbalance Mitochondrial dysfunctionOxidative stress pathwaysAbnormal gut microbiota  Direct consequence of viral injury involvement, resulting in ME/CFS-like patogenesis, host cell-mediated immune response mechanism, and neurotropism using a transsynaptic spread mechanism (hypoxic driven neuronal apoptosis)
  Indirect consequence on mental health due to posttraumatic stress, social isolation, and economic factors, such as loss of employmentIndirect consequence on mental healthPICS-like patogenesis: adverse therapy effects prolonged immobilisation immunologic alterationsVasculitis involvement 
Prolonged symptomes  >6 months  >3 months   
Functional mobility impairment  +/++  +/++  ++/+++ 
General and constitutional symptoms: fatigue or muscle weakness, joint and muscle pain, flu-like symptoms, …  ++  ++  ++/+++ 
Pulmonary abnormalities  −/+  −/+  +++ 
Cardiovascular disorders  −/+  −/+  ++/+++ 
Neurologic symptoms and dysautonomia  +/++  +/++  ++/+++ 
Gastrointestinal disorders  ++  ++  ++ 
Mental health disorders  ++  ++  ++/+++ 
Treatment  Follow-up multidisciplinary treatment programme:Pharmacological treatment based on symptomatologyEducationPhysical exerciseCognitive behavioural therapy

First cluster, those patients who had mild symptoms and did not required hospitalisation (outpatient care), and develop persistent symptomes after the acute episode, so-called post-COVID-19 fatigue syndrome (PCFS). Many clinical similarities and common pathophysiological features may exite between ME/CFS and PCFS patients (ME/CFS-like).

Second cluster, those patients who required admission to hospital for severe COVID-19 (ICU or non-ICU ward hospitalisation), and develop persistent symptomes after discharge, so-called post-acute COVID-19 syndrome (PACS). Thus, ICU-PACS patients should be differentiated and ICD-10 identified from post-intensive care syndrome (PICS) defining as “new or worsening impairment of cognition, mental health or physical function after critical illness, persisting beyond the acute care hospitalisation”.5 Although some differences between ICU-PACS and PICS exist that may likely reflect the variable impact, the symptoms of both entities may be related, ex aqua, to immunology alterations, vacuities involvement, adverse therapy effects, prolonged immobilisation, and mitochondrial dysfunction.

Taking into account the high grade of evidence of the multidisciplinary treatment programme, composed by the combination of pharmacological treatment based on symptomatology, education, physical exercise and cognitive behavioural therapy, in ME/CFS patients, we believe that the implementation of this follow-up programme might be an effective in Long COVID-19 patients.

In summary, Long COVID-19 should be considered a public Health emergency. Well-conducted studies are needed to identify the real prevalence, phenotypes, risk predictors, future treatments, and the potential differences with ME/CFS and other overlapping pathological entities (PICS).


Clinical manifestations and pathophysiological features of Long COVID-19 can lead to symptoms commonly presented in patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. We present similarities and differences of both entities. Management of both entities may be similar.

Funding sources

Author declares no funding sources.

Conflict of interest

Author declares no conflict of interest.

D. Groff, A. Sun, A.E. Ssentongo, D.M. Ba, N. Parsons, G.R. Poudel, et al.
Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review.
JAMA Netw Open, 4 (2021), pp. e2128568
J.B. Soriano, S. Murthy, J.C. Marshall, P. Relan, J.V. Diaz, WHO Clinical Case Definition Working Group on Post-COVID-19 Condition.
A clinical case definition of post-COVID-19 condition by a Delphi consensus.
B.M. Carruthers, A.K. Jain, K.L. de Meirleir, D.L. Peterson, N.J. Filmas, A.M. Lermer, et al.
Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols.
J Chron Fatigue Syndr, 11 (2003), pp. 7-115
J. Fernández-Solá.
Chronic fatigue syndrome: current situation.
Rev Clin Esp, 211 (2011), pp. 407-409
J. Rello, A. James, L.F. Reyes.
Post-acute COVID-19 syndrome (PACS): a public health emergency.
Anaesth Crit Care Pain Med, 40 (2021), pp. 100882
Copyright © 2022. Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología
Reumatología Clínica (English Edition)
Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?